Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies

[Background] Patients with relapsed/refractory multiple myeloma (RRMM) who develop extramedullary disease (EMD) generally have a poor prognosis, highlighting the urgent need for new therapies. We report effectiveness outcomes and safety in patients with and without EMD from the pooled analysis of Lo...

Descripción completa

Detalles Bibliográficos
Autores: Moreau, Philippe, Mateos, Maria Victoria, Goldschmidt, Hartmut, González García, María-Esther, Besemer, Britta, González Pérez, Marta Sonia, Mohty, Mohamad, Lindsey-Hill, Joanne, Kirkpatrick, Suriya, Delforge, Michel, Angelucci, Emanuele, Raimondo, Francesco Di, Vij, Ravi, Doyle, Margaret, Gray, Kathleen, Albrecht, Claire, Strulev, Vadim, Haddad, Imène, Koskinen, Silva, Acciarri, Lorenzo, Buyze, Jozefien, Weisel, Katja
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:dnet:digitalcsic_::943641df23d30fe56c0f7d2573901af1
Acceso en línea:http://hdl.handle.net/10261/426142
https://api.elsevier.com/content/abstract/scopus_id/105003942547
Access Level:acceso abierto
Palabra clave:Extramedullary plasmacytoma
Real-life outcomes
Prospective
Standard-of-care
Treatment
Descripción
Sumario:[Background] Patients with relapsed/refractory multiple myeloma (RRMM) who develop extramedullary disease (EMD) generally have a poor prognosis, highlighting the urgent need for new therapies. We report effectiveness outcomes and safety in patients with and without EMD from the pooled analysis of LocoMMotion and MoMMent.

Similares en LA Referencia